The stock of Innocare Pharma Limited (ASX: 688428) closed higher today.

At the time of writing, Innocare Pharma Limited (ASX: 688428) closed at 29.10 yuan, marking a gain of 4.49%. Trading volume reached 3.83 billion yuan, with a turnover rate of 4.94% and a volume ratio of 0.83. The intraday price fluctuation was 8.55%. The share price faces near-term resistance around the previous high of 31.91 yuan.

Key Financial Performance

For the 2025 fiscal year, the company reported revenue of 2.37 billion yuan, a substantial increase of 135% year-over-year. Net profit attributable to shareholders reached 642 million yuan, surging 246% year-over-year, indicating explosive growth in both top and bottom lines.

For the first quarter of 2026, net profit attributable to shareholders was 106 million yuan, soaring 488.93% compared to the same period last year, maintaining an exceptionally high growth rate for the quarter.

Analyst Consensus Forecasts

Consensus estimates project revenue for 2026 at 2.36 billion yuan, representing a slight decrease of 0.51% year-over-year, with net profit forecast at 227 million yuan, a decline of 64.7%. For 2027, revenue is expected to be 2.62 billion yuan, an increase of 10.8%, while net profit is anticipated to be 200 million yuan, down 11.7%.

Business Segment Breakdown

The company's revenue structure is dominated by drug sales, which account for 60.73%. Technology licensing contributes 38.07% of revenue, while R&D services and testing services make up 1.11% and 0.09%, respectively. The company's core operations focus on the commercial sales of innovative drugs and pharmaceutical technology licensing partnerships.

The information presented is based on publicly available data and is not intended as investment advice.